Indacaterol (Arcapta)
Indications
Pharmacology
- Ultra Long-Acting β2-Adrenergic Receptor Agonist (see β2-Adrenergic Receptor Agonists, [[β2-Adrenergic Receptor Agonists]]): 24 hr sustained bronchodilation
- Improved FEV1: fast onset of action (FEV1 improvement is seen as early as 5 min after dose)
- Decreased rescue medication use
- Improved health-related quality of life (by St. George’s respiratory questionnaire)
Administration
- INH: 75 ug qday (dry powder capsule, used in neohaler device)
Adverse Effects
Pulmonary Adverse Effects
- Cough (see Cough, [[Cough]])
- Nasopharyngitis (see Pharyngitis, [[Pharyngitis]])
- LABA FDA Black-Box Warning in Asthma: all LABA’s carry this warning, although indacaterol is not indicated for asthma
Gastrointestinal Adverse Effects
Neurological Adverse Effects
Other Adverse Effects
References